文献速递免疫规划传染病防控与疫情报告

北卡罗来纳州COVID-19社区研究伙伴项目参与者中疫苗诱导的血清阳转

Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
PubMed 文献 · Vaccine · 2022-09-12

在北卡罗来纳州近8000名成年人队列中,采用居家自采指尖血即时检测评估mRNA COVID-19疫苗接种后血清阳转率。91.4%的参与者在首次接种后75天内记录到血清阳转(中位31天);年龄较大者、男性、接种BNT162b2者血清阳转可能性较低,有既往感染证据者及接种第二剂后报告新症状者较高。

要点

  • 91.4%接种者首次接种后75天内血清阳转,中位31天。
  • 41-65岁和66-95岁成人血清阳转可能性低于18-40岁。
  • 男性、接种BNT162b2者血清阳转可能性较低。

核心结论

  • 数据表明COVID-19疫苗在社区水平具有高免疫原性,但在老年人中存在显著差异,且居家自采即时检测用于社区队列监测具有可行性。

研究设计与样本

  • 在北卡罗来纳州近8000名成年人中开展的队列研究,参与者报告至少接种1剂mRNA COVID-19疫苗,采用居家自采即时检测评估血清阳转。

主要发现

  • 总体91.4%的参与者在首次接种后75天内记录到血清阳转,中位31天。
  • 与18-40岁相比,41-65岁成人血清阳转可能性较低(校正风险比[aHR] 0.69,95%CI 0.64-0.73),66-95岁成人亦较低(aHR 0.55,95%CI 0.50-0.60)。
  • 与女性相比,男性血清阳转可能性较低(aHR 0.92,95%CI 0.87-0.98)。
  • 有既往感染证据者血清阳转可能性高于无既往感染者(aHR 1.50,95%CI 1.19-1.88)。
  • 接种BNT162b2者血清阳转可能性低于接种mRNA-1273者(aHR 0.84,95%CI 0.79-0.90);第二剂后报告至少一种新症状者血清阳转可能性较高(aHR 1.11,95%CI 1.05-1.17)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Well-regulated clinical trials have shown FDA-approved COVID-19 vaccines to be immunogenic and highly efficacious. We evaluated seroconversion rates in adults reporting ≥ 1 dose of an mRNA COVID-19 vaccine in a cohort study of nearly 8000 adults residing in North Carolina to validate immunogenicity using a novel approach: at-home, participant administered point-of-care testing. Overall, 91.4% had documented seroconversion within 75 days of first vaccination (median: 31 days). Participants who were older and male participants were less likely to seroconvert (adults aged 41-65: adjusted hazard ratio [aHR] 0.69 [95% confidence interval (CI): 0.64, 0.73], adults aged 66-95: aHR 0.55 [95% CI: 0.50, 0.60], compared to those 18-40; males: aHR 0.92 [95% CI: 0.87, 0.98], compared to females). Participants with evidence of prior infection were more likely to seroconvert than those without (aHR 1.50 [95% CI: 1.19, 1.88]) and those receiving BNT162b2 were less likely to seroconvert compared to those receiving mRNA-1273 (aHR 0.84 [95% CI: 0.79, 0.90]). Reporting at least one new symptom after first vaccination did not affect time to seroconversion, but participants reporting at least one new symptom after second vaccination were more likely to seroconvert (aHR 1.11 [95% CI: 1.05, 1.17]). This data demonstrates the high community-level immunogenicity of COVID-19 vaccines, albeit with notable differences in older adults, and feasibility of using at-home, participant administered point-of-care testing for community cohort monitoring. Trial registration: ClinicalTrials.gov NCT04342884.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Friedman-Klabanoff DJ, Tjaden AH, Santacatterina M, et al. Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership. Vaccine. 2022. PMID: 36117003. doi:10.1016/j.vaccine.2022.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。